Gene · 4593
Papers3,141
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 3,141
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A satellite cell-dependent epigenetic fingerprint in skeletal muscle identity genes after lifelong physical activity. | FASEB J | 2025 | 40047419 | PubTator, text mining | PubMed |
| Single-nuclei sequencing of skeletal muscle reveals subsynaptic-specific transcripts involved in neuromuscular junction maintenance. | Nat Commun | 2025 | 40044687 | PubTator, text mining | PubMed |
| Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions. | J Neuromuscul Dis | 2025 | 40033991 | PubTator, text mining | PubMed |
| Unusual presentations of myasthenia gravis and misdiagnosis. | Sci Rep | 2025 | 40032968 | PubTator, text mining | PubMed |
| Efficacy and safety of rituximab in anti-MuSK myasthenia Gravis: a systematic review and meta-analysis. | Sci Rep | 2025 | 40021769 | PubTator, text mining | PubMed |
| Young child with MuSK myasthenia gravis: treatment and remission with rituximab. | BMJ Case Rep | 2025 | 40000033 | PubTator, text mining | PubMed |
| Clinical Outcomes of Rituximab Infusion Among Refractory Myasthenia Gravis Patients in the Philippines: A 10-Year Retrospective Study. | Cureus | 2025 | 39991399 | PubTator, text mining | PubMed |
| Progress in research on the formation mechanism, chemical composition, pharmacological effects, and clinical applications of Musk: A Review. | J Ethnopharmacol | 2025 | 39971015 | PubTator, text mining | PubMed |
| Autoantibodies in myasthenia gravis: cluster analysis and clinical correlations. | Front Neurol | 2025 | 39968461 | PubTator, text mining | PubMed |
| Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models. | iScience | 2025 | 39898046 | PubTator, text mining | PubMed |
| Orbicularis Oculi Stimulated Jitter Analysis in Children With Autoimmune Myasthenia Gravis. | Muscle Nerve | 2025 | 39887421 | PubTator, text mining | PubMed |
| MuSK Regulates Neuromuscular Junction Nav1.4 Localization and Excitability. | J Neurosci | 2025 | 39880682 | PubTator, text mining | PubMed |
| Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. | Lancet Neurol | 2025 | 39862880 | PubTator, text mining | PubMed |
| Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. | Lancet Neurol | 2025 | 39862879 | PubTator, text mining | PubMed |
| Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study. | Ther Adv Neurol Disord | 2025 | 39839222 | PubTator, text mining | PubMed |
| Whole Exome Sequencing Reveals Candidate Variants in Ion Channel Genes for Pelvic Muscle Dysfunction in Young Females with a Family History. | Int Urogynecol J | 2025 | 39833541 | PubTator, text mining | PubMed |
| Biallelic variants in AGRN in a family with recurrent pregnancy losses and fetal akinesia deformation sequence. | Clin Dysmorphol | 2025 | 39807604 | PubTator, text mining | PubMed |
| A vision-language foundation model for precision oncology. | Nature | 2025 | 39779851 | PubTator, text mining | PubMed |
| Advances in Disease-Modifying Therapeutics for Chronic Neuromuscular Disorders. | Semin Respir Crit Care Med | 2025 | 39708835 | PubTator, text mining | PubMed |
| Regeneration mechanisms and therapeutic strategies for neuromuscular junctions in aging and diseases. | Neural Regen Res | 2025 | 39657086 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4593/papers?page=10